This likely reflects an increased ability of these patients to interact with others and with their environment due to improved mobility, improved sleep, and/or reductions in respiratory disease burden, since idursulfase does not cross the blood–brain barrier (Boado et al 2013). The gene discussed is IDS; the disease is respiratory system disorder.